EUVIMEDEUVIMED entdecken
Open Access

Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2 -Positive Metastatic Breast Cancer

Jean-Sebastien Frenel, Jean Zeghondy, Catherine Guérin-Charbonnel, Audrey Mailliez, Elsa Volant, François Poumeaud, Anne Patsouris, Monica Arnedos, Caroline Bailleux, Julie Cabal, Loick Galland, Alexandre de Nonneville und 9 weitere

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.4435 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Jean-Sebastien Frenel und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Brain Neoplasms, Oxazoles, Pyridines. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2 )-positive metastatic breast cancer (MBC).

Objective

To investigate outcomes following TTC treatment in patients with ERBB2 -positive MBC who had previously received trastuzumab-deruxtecan. Design, Setting, and Participants This cohort study included all patients with MBC who were treated in 12 French comprehensive cancer centers between August 1, 2020, and December 31, 2022. Exposure Tucatinib combined with trastuzumab and capecitabine administered at the recommended dose. Main Outcomes and Measures Clinical end points included progression-free survival (PFS), time to next treatment (TTNT), overall survival (OS), and overall response rate (ORR).

Results

A total of 101 patients with MBC were included (median age, 56 [range, 31-85] years). The median number of prior treatment lines for metastatic disease at TTC treatment initiation was 4 (range, 2-15), including 82 patients (81.2%) with previous trastuzumab and/or pertuzumab and 94 (93.1%) with previous ado-trastuzumab-emtansine) exposure. The median duration of trastuzumab-deruxtecan treatment was 8.9 (range, 1.4-25.8) months, and 82 patients (81.2%) had disease progression during trastuzumab-deruxtecan treatment, whereas 18 (17.8%) had stopped trastuzumab-deruxtecan for toxic effects and 1 (1.0%) for other reasons. Tucatinib combined with trastuzumab and capecitabine was provided as a third- or fourth-line treatment in 37 patients (36.6%) and was the immediate treatment after trastuzumab-deruxtecan in 86 (85.1%). With a median follow-up of 11.6 (95% CI, 10.5-13.4) months, 76 of 101 patients (75.2%) stopped TTC treatment due to disease progression. The median PFS was 4.7 (95% CI, 3.9-5.6) months; median TTNT, 5.2 (95% CI, 4.5-7.0) months; and median OS, 13.4 (95% CI, 11.1 to not reached [NR]) months. Patients who received TTC immediately after trastuzumab-deruxtecan had a median PFS of 5.0 (95% CI, 4.2-6.0) months; median TTNT of 5.5 (95% CI, 4.8-7.2) months, and median OS of 13.4 (95% CI, 11.9-NR) months. Those who received TTC due to trastuzumab-deruxtecan toxicity-related discontinuation had a median PFS of 7.3 (95% CI, 3.0-NR) months. Best ORR was 29 of 89 patients (32.6%). Sixteen patients with active brain metastasis had a median PFS of 4.7 (95% CI, 3.0-7.3) months, median TTNT of 5.6 (95% CI, 4.4 to NR), and median OS of 12.4 (95% CI, 8.3-NR) months. Conclusions and Relevance In this study, TTC therapy was associated with clinically meaningful outcomes in patients with ERBB2 -positive MBC after previous trastuzumab-deruxtecan treatment, including those with brain metastases. Prospective data on optimal drug sequencing in this rapidly changing therapeutic landscape are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBrain NeoplasmsOxazolesPyridinesQuinazolinesHumansMiddle AgedFemaleCapecitabineCohort StudiesProspective StudiesTrastuzumabDisease ProgressionErb-b2 Receptor Tyrosine Kinases

Substanzen

CapecitabineTrastuzumabErb-b2 Receptor Tyrosine KinasesOxazolesPyridinesQuinazolinestucatinibERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.
  • Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France.
  • Department of Biostatistics and Analytics, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.
  • Department of Medical Oncology, Oscar Lambret Comprehensive Cancer Center, Lille, France.
  • Department of Medical Oncology, Oncopôle, Toulouse, France.
  • Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Angers, France.

Zitieren

APA

Frenel, J. S., Zeghondy, J., Guérin-Charbonnel, C., Mailliez, A., Volant, E., Poumeaud, F., Patsouris, A., Arnedos, M., Bailleux, C., Cabal, J., Galland, L., de Nonneville, A., Guiu, S., Dalenc, F., Pistilli, B., Bachelot, T., Pierga, J. Y., Le Du, F., Bocquet, F., …, & Loirat, D. (2024). Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2 -Positive Metastatic Breast Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.4435

Vancouver

Frenel JS, Zeghondy J, Guérin-Charbonnel C, Mailliez A, Volant E, Poumeaud F, et al. Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2 -Positive Metastatic Breast Cancer. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.4435

BibTeX
@article{Frenel2024,
  author = {Frenel, Jean-Sebastien and Zeghondy, Jean and Guérin-Charbonnel, Catherine and Mailliez, Audrey and Volant, Elsa and Poumeaud, François and Patsouris, Anne and Arnedos, Monica and Bailleux, Caroline and Cabal, Julie and Galland, Loick and de Nonneville, Alexandre and Guiu, Séverine and Dalenc, Florence and Pistilli, Barbara and Bachelot, Thomas and Pierga, Jean-Yves and Le Du, Fanny and Bocquet, François and Larrouquere, Louis and Loirat, Delphine},
  title = {Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2 -Positive Metastatic Breast Cancer},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.4435}
}
Kostenlos starten →